: FTC orders Illumina to divest Grail; Illumina plans to appeal
The Federal Trade Commission on Monday ordered Illumina Inc. ILMN to divest Grail Inc., saying that “the deal would stifle competition and innovation in the U.S. market for life-saving cancer tests.” Illumina said it will appeal the decision in a federal appeals court, thus staying the order until an appeals verdict is reached. Grail makes non-invasive, multi-cancer early detection (MCED) tests that use DNA sequencing to screen for cancers in patients who are asymptomatic. The FTC’s release said that Illumina “is currently... Читать дальше...